<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство и гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0300-9092</issn><issn publication-format="electronic">2412-5679</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">631627</article-id><article-id pub-id-type="doi">10.18565/aig.2024.21</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Satisfaction of young women with Estradiol Valerate/Dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN</article-title><trans-title-group xml:lang="ru"><trans-title>Удовлетворенность молодых женщин препаратом Эстрадиола Валерат/Диеногест в реальной клинической практике в России: результаты проспективного многоцентрового наблюдательного исследования «Лебедь»</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3993-7629</contrib-id><name-alternatives><name xml:lang="en"><surname>Prilepskaya</surname><given-names>Vera N.</given-names></name><name xml:lang="ru"><surname>Прилепская</surname><given-names>Вера Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Scientific Polyclinic Department</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заслуженный деятель науки РФ, руководитель научно-поликлинического отделения</p></bio><email>vprilepskaya@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>Elena N.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>Елена Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Professor, Deputy Director – Director of the Institute of Reproductive Medicine, Professor at the Department of Obstetrics, Gynecology and Reproductive Medicine</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, врач высшей квалификационной категории, заместитель директора Центра – директор Института репродуктивной медицины, профессор кафедры акушерства, гинекологии и репродуктивной медицины </p></bio><email>gynec@endocrincentr.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">National Medical Research Center for Endocrinology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian University of Medicine, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Российский университет медицины» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-03-04" publication-format="electronic"><day>04</day><month>03</month><year>2024</year></pub-date><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>108</fpage><lpage>117</lpage><history><date date-type="received" iso-8601-date="2024-05-04"><day>04</day><month>05</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-05-04"><day>04</day><month>05</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО «Бионика Медиа»</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0300-9092/article/view/631627">https://journals.eco-vector.com/0300-9092/article/view/631627</self-uri><abstract xml:lang="en"><p>Objective: To evaluate satisfaction in young women (18–35 years old) with a drug containing estradiol valerate/dienogest (E2V/DNG) over a 6-month period in real clinical practice in Russia.</p> <p>Materials and methods: This was a prospective multicenter study that assessed satisfaction of 504 women (average age is 27.8 years) with the contraceptive containing E2V/DNG. The characteristics of menstrual bleeding, sexual function, and women’s decision to continue using the contraceptive were evaluated in two subgroups: in the presence and absence of abnormal uterine bleeding (AUB). The satisfaction of doctors with this method of contraception was also assessed.</p> <p>Results: It was found that 98.4% of women and 100% of doctors were “very satisfied” or “satisfied” with this method of contraception, regardless of the presence or absence of AUB. There was a significant decrease in the intensity, duration of menstrual bleeding and pain, and in the frequency of intermenstrual bleeding compared with the baseline indicator. Normalization of the parameters of the FSFI questionnaire was observed in most of the patients (89.7%), although initially these parameters could indicate sexual dysfunction in almost half of the patients (46.0%). The contraceptive E2V/DNG was well tolerated by women, and the overall rate of adverse events was 7.1%. Most women (97.8%) decided to continue taking the medication after completing the study.</p> <p>Conclusion: The results of the study showed high satisfaction of young Russian women and doctors with the use of E2V/DNG, regardless of the presence or absence of AUB. The medication has a positive effect on the characteristics of bleeding/cycle control and on the quality of sexual function, therefore, the women demonstrated a high adherence to this method of contraception.</p></abstract><trans-abstract xml:lang="ru"><p>Цель: Оценить удовлетворенность лекарственным препаратом, содержащим эстрадиола валерат/диеногест (Э2В/ДНГ), среди молодых женщин (18–35 лет) за 6-месячный период в условиях реальной клинической практики в России.</p> <p>Материалы и методы: В проспективном многоцентровом исследовании оценивалась удовлетворенность препаратом Э2В/ДНГ, применяемым с целью контрацепции, среди 504 женщин (средний возраст 27,8 года). Проводилась оценка профиля менструальных кровотечений, сексуальной функции, решения женщин о продолжении использования препарата отдельно в двух подгруппах: при наличии и отсутствии исходных обильных менструальных кровотечений (ОМК). Оценивалась также удовлетворенность врачей данным методом контрацепции.</p> <p>Результаты: Установлено, что 98,4% женщин и 100% врачей были «очень довольны» или «довольны» используемым методом контрацепции, независимо от наличия или отсутствия у пациенток исходных ОМК. Отмечено значительное снижение интенсивности, продолжительности менструальных кровотечений и боли, частоты межменструальных кровотечений по сравнению с исходным показателем. У большинства участниц (89,7%) наблюдалась нормализация показателей опросника FSFI, хотя исходно почти у половины пациенток (46,0%) они могли указывать на нарушение сексуальной функции. Препарат Э2В/ДНГ хорошо переносился женщинами, общая частота нежелательных явлений составила 7,1%. Большинство женщин (97,8%) решило продолжить прием препарата после завершения исследования.</p> <p>Заключение: Показана высокая удовлетворенность молодых российских женщин и врачей использованием Э2В/ДНГ независимо от наличия или отсутствия исходных ОМК. Препарат оказывает положительное влияние на профиль кровотечений/контроль цикла и на качество сексуальной функции, что нашло отражение в высокой приверженности женщин данному методу контрацепции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>combined oral contraceptives</kwd><kwd>young women</kwd><kwd>estradiol valerate</kwd><kwd>dienogest</kwd><kwd>real clinical practice</kwd><kwd>satisfaction</kwd><kwd>characteristics of bleeding</kwd><kwd>sexual function</kwd><kwd>adherence</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>комбинированные оральные контрацептивы</kwd><kwd>молодые женщины</kwd><kwd>эстрадиола валерат</kwd><kwd>диеногест</kwd><kwd>реальная клиническая практика</kwd><kwd>удовлетворенность</kwd><kwd>профиль кровотечений</kwd><kwd>сексуальная функция</kwd><kwd>приверженность</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Дикке Г.Б. Потребности, ожидания и сомнения у пользователей гормональными контрацептивами. Гинекология. 2020; 22(1): 33-7. [Dikke G.B. Needs, expectations and doubt users of hormonal contraceptives. Gynecology. 2020; 22(1): 33-7. (in Russian)]. https://dx.doi.org/10.26442/ 20795696.2020.1.200044.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Шереметьева Е.В., Андреева Е.Н. Индивидуальное консультирование молодых женщин по вопросам контрацепции в реальной клинической практике. Проблемы репродукции. 2022; 28(4): 89-96. [Sheremetyeva E.V., Andreeva E.N. Individualized contraceptive counseling for young women in clinical practice. Russian Journal of Human Reproduction. 2022; 28(4): 89-96. (in Russian)]. https://dx.doi.org/10.17116/repro20222804189.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nappi R.E., Vermuyten N., Bannemerschult R. Missed opportunities in contraceptive counselling: findings from a European survey-based study with simulated patient consultation. Eur. J. Contracept. Reprod. Health Care. 2022; 27(2): 85-94. https://dx.doi.org/10.1080/13625187.2021.2010040.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bitzer J., Marin V., Lira J. Contraceptive counselling and care: a personalized interactive approach. Eur. J. Contracept. Reprod. Health Care. 2017; 22(6): 418-23. https;//dx.doi.org/10.1080/13625187.2017.1414793.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cavallaro F.L., Benova L., Owolabi O.O., Ali M. A systematic review of the effectiveness of counselling strategies for modern contraceptive methods: what works and what doesn't? BMJ Sex. Reprod. Health. 2020; 46(4): 254-69. https://dx.doi.org/10.1136/bmjsrh-2019-200377.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>FSRH Clinical Effectiveness Unit. FSRH clinical guideline: combined hormonal contraception (January 2019, Amended October 2023). https://dx.doi.org/10.1136/bmjsrh-2018-CHC.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Прилепская В.Н., Абакарова П.Р., Яроцкая Е.Л. Современная контрацепция и качество жизни женщины. Доктор Ру. 2017; 3: 37-42. [Prilepskaya V.N., Abakarova P.R., Yarotskaya Ye.L. Modern Contraception and Women’s Quality of Life. Doctor.Ru. 2017; (3): 37-42. (in Russian)].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Дикке Г.Б. Отказ от ранее выбранного метода контрацепции и стратегии повышения приверженности. Проблемы репродукции. 2017; 23(5): 54-60. [Dikke G.B. Failure from the previously selected method of contraception and strategy for improving commitment. Russian Journal of Human Reproduction. 2017; 23(5): 54-60. (in Russian)]. https://dx.doi.org/10.17116/ repro201723554-60.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Le Guen M., Schantz C., Règnier-Loilier A., de La Rochebrochard E. Reasons for rejecting hormonal contraception in Western countries: A systematic review. Soc. Sci. Med. 2021; 284: 114247. https://dx.doi.org/ 10.1016/j.socscimed.2021.114247.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur. J. Contracept. Reprod. Health Care. 2016; 21(2): 93-105. https://dx.doi.org/10.3109/13625187.2015.1077380.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Андреева Е.Н., Шереметьева Е.В. Режимы контрацепции: повышение приверженности женщин современным комбинированным оральным контрацептивам с максимально коротким безгормональным интервалом. Гинекология. 2020; 22(2): 46-50. [Andreeva E.N., Sheremetyeva E.V. Contraception modes: increasing women’s commitment to modern combined oral contraceptives with the shortest possible hormone-free interval. Gynecology. 2020; 22(2): 46-50. (in Russian)]. https://dx.doi.org/10.26442/ 20795696.2020.2.200128.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Актуальная версия инструкции препарата «Клайра» от 31.05.2023. Номер РУ: ЛП-№ (002448)-(РГ-RU). [The current version of the instructions of the drug Qlaira dated 05/31/2023. RU number: LP-No. (002448)-(RG-RU). (in Russian)].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Nelson A., Parke S., Mellinger U., Zampaglione E., Schmidt A. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J. Womens Health (Larchmt). 2014; 23(3): 204-10. https://dx.doi.org/10.1089/ jwh.2013.4320.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Yu Q., Huang Z., Ren M., Chang Q., Zhang Z., Parke S. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study. Int. J. Womens Health. 2018; 10: 257-66. https://dx.doi.org/10.2147/IJWH.S157056.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Petraglia F., Parke S., Serrani M., Mellinger U., Römer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. Int. J. Gynaecol. Obstet. 2014; 125(3): 270-4. https://dx.doi.org/10.1016/j.ijgo.2013.11.017.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Macìas G., Merki-Feld G.S., Parke S., Mellinger U., Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J. Obstet. Gynaecol. 2013; 33(6): 591-6. https://dx.doi.org/10.3109/01443615.2013. 800851.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Dinger J., Möhner S., Heinemann K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Front. Womens Health. 2020; 5: 1-8. https://dx.doi.org/10.15761/FWH.1000178.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ahrendt H.J., Makalová D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44. https://dx.doi.org/10.1016/j.contraception.2009.03.018.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Fraser I.S., Parke S., Mellinger U., Machlitt A., Serrani M., Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur. J. Contracept. Reprod. Health Care. 2011; 16(4): 258-69. https://dx.doi.org/10.3109/ 13625187.2011.591456.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Haverinen A.H., Luiro K.M., Szanto T., Kangasniemi M.H., Hiltunen L., Sainio S. et al. Combined oral contraceptives containing estradiol valerate vs ethinylestradiol on coagulation: A randomized clinical trial. Acta Obstet. Gynecol. Scand. 2022; 101(10): 1102-11. https://dx.doi.org/10.1111/aogs.14428.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Meston C.M., Freihart B.K., Handy A.B., Kilimnik C.D., Rosen R.C. Scoring and interpretation of the FSFI: What can be learned from 20 years of use? J. Sex. Med. 2020; 17(1): 17-25. https://dx.doi.org/10.1016/j.jsxm.2019.10.007.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Briggs P., Serrani M., Vogtländer K., Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int. J. Womens Health. 2016; 8: 477-87. https://dx.doi.org/10.2147/IJWH.S107586.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Barnett C., Dinger J., Minh T.D., Heinemann K. Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study. Eur. J. Contracept. Reprod. Health Care. 2019; 24(4): 247-50. https://dx.doi.org/10.1080/13625187.2019.1629412.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Прилепская В.Н., Довлетханова Э.Р. Гормональная контрацепция с применением комбинированного перорального контрацептива, содержащего эстрадиола валерат/диеногест. Медицинский оппонент. 2022; 2: 46-52. [Prilepskaya V.N., Dovletkhanova E.R. Hormonal сontraception using a combined oral contraceptive containing estradiol valerate/dienogest. Medical. Opponent. 2022; (2): 46-52. (in Russian)].</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Young M.F., Oaks B.M., Tandon S., Martorell R., Dewey K.G., Wendt A.S. Maternal hemoglobin concentrations across pregnancy and maternal and child health: a systematic review and meta-analysis. Ann. N. Y. Acad. Sci. 2019; 1450(1): 47-68. https://dx.doi.org/10.1111/nyas.14093.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Куценко И.И., Кравцова Е.И., Холина Л.А., Томина О.В. Терапия латентного железодефицитного состояния у беременных. Гинекология. 2022; 24(6): 512-7. [Kutsenko I.I., Kravtsova E.I., Kholina L.A., Tomina O.V. Latent iron deficiency therapy in pregnant women. Gynecology. 2022; 24(6): 512-7. (in Russian)]. https://dx.doi.org/10.26442/20795696.2022.6.202023.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Jensen J.T., Bitzer J., Nappi R.E., Ahlers C., Bannemerschult R., Parke S. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur. J. Contracept. Reprod. Health Care. 2020; 25(2): 98-105. https://dx.doi.org/10.1080/13625187.2020.1731734.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Palacios S., Wildt L., Parke S., Machlitt A., Römer T., Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 149(1): 57-62. https://dx.doi.org/10.1016/j.ejogrb.2009.11.001.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Davis S.R., Bitzer J., Giraldi A., Palacios S., Parke S., Serrani M. et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-79. https://dx.doi.org/10.1111/jsm.12310.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Caruso S., Agnello C., Romano M., Cianci S., Lo Presti L., Malandrino C., Cianci A. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J. Sex. Med. 2011; 8(10): 2841-50. https://dx.doi.org/10.1111/ j.1743-6109.2011.02409.x.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>De Seta F., Restaino S., Banco R., Conversano E., De Leo R., Tonon M. et al. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol. Endocrinol. 2014; 30(11): 830-5. https://dx.doi.org/ 10.3109/09513590.2014.936847.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Di Carlo C., Gargano V., De Rosa N., Tommaselli G.A., Sparice S., Nappi C. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age. Gynecol. Endocrinol. 2014; 30(12): 925-8. https://dx.doi.org/10.3109/09513590.2014.975688.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Юренева С.В., Ильина Л.М. Комбинированные оральные контрацептивы с натуральным эстрогеном и сексуальная функция: оптимальный метод контрацепции для женщин различного возраста. Гинекология. 2019; 21(1): 33-7. [Yureneva S.V., Ilina L.M. Combined oral contraceptives with natural estrogen and sexual function: the optimal method of contraception for women of different ages. Gynecology. 2019; 21(1): 33-7. (in Russian)]. https://dx.doi.org/ 10.26442/20795696.2019.1.190184.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>de Castro Coelho F., Barros C. The potential of hormonal contraception to influence female sexuality. Int. J. Reprod. Med. 2019; 2019: 9701384. https://dx.doi.org/10.1155/2019/9701384.</mixed-citation></ref></ref-list></back></article>
